eXoZymes Inc. SEC filings document a Nevada biotechnology issuer with common stock listed on the Nasdaq Capital Market under the symbol EXOZ. The filing record is centered on Form 8-K Item 8.01 current reports that furnish investor presentations, press releases, and exhibit materials.
These filings disclose company communications about the exozyme cell-free biomanufacturing platform, NCTx business materials, NCT production scale-up, commercial-readiness updates, and capital-markets presentation materials associated with securities offering activity. They also identify the registered common stock class, exchange listing, exhibit filings, and formal signatures required under Exchange Act reporting.
EXOZYMES INC. Chief Commercial Officer Damien Alan Perriman converted 3,922 restricted stock units into 3,922 common shares on October 9, 2026, on a one-for-one basis with no consideration paid. The units came from a grant of 62,759 on April 1, 2026, vesting periodically; 39,225 restricted stock units were reported following the conversion. On October 12, 2026, he sold 3,729 common shares to cover tax withholding obligations, at a weighted-average price of $5.2096 per share across trades priced from $5.15 to $5.25. No Rule 10b5-1 plan is reported.
Exozymes Inc. amended a prior report to correct an erroneously reported conversion by Tyler Paz Korman, its Chief Scientific Officer. The 32,964 restricted stock units did not convert on August 19, 2026, and no shares were issued. After removing the erroneous entry, reported holdings were 79,104 outstanding restricted stock units and 729,123 shares of common stock.
Exozymes Inc. director Edgardo Javier Rayo received a grant of 25,000 stock options on October 1, 2026, with an exercise price of $6.28 per share and an expiration date of October 1, 2033. The options vest in twelve quarterly installments: eleven installments of 2,083 shares and a final installment of 2,087 shares, beginning December 31, 2026 and ending September 30, 2029, subject to his continued service. The report also lists his direct ownership of 77,909 common shares on October 1, 2026.
Christopher A. Marlett, a director and 10% owner of EXOZ, received a direct award of options to buy 10,000 shares on October 1, 2026, with a $6.28 exercise price and an October 1, 2033 expiration. The options vest quarterly from December 31, 2026, through September 30, 2029, subject to his continued service with the issuer. Separately, MDB Capital Holdings, LLC held 3,808,476 common shares as of October 1, 2026. Marlett has voting and dispositive authority over those shares and disclaims any interest except to the extent of his pecuniary interests in the LLC.
Exozymes Inc. director James Joseph Lalonde received a grant of 10,000 stock options to buy common stock on October 1, 2026, with an exercise price of $6.28 per share. The options vest in 12 quarterly installments: 11 installments of 833 shares and a final installment of 837 shares, beginning December 31, 2026, and ending September 30, 2029, subject to the reporting person's continued service with the issuer.
ExoZymes Inc. (EXOZ) granted director and 10% owner Anthony Digiandomenico a stock option covering 10,000 common shares on October 1, 2026. The option has a $6.28 exercise price and vests in 12 quarterly installments—11 installments of 833 shares and a final installment of 837 shares—beginning December 31, 2026 and ending September 30, 2029, subject to his continued service. It expires October 1, 2033.
Separately, MDB Capital Holdings, LLC held 3,808,476 common shares as of October 1, 2026. Digiandomenico has voting and dispositive authority over those shares and disclaims any interest in them except to the extent of his pecuniary interests in the LLC.
EXOZYMES INC. director James Ulrich Bowie received an option award covering 10,000 shares of common stock on October 1, 2026. The option has an exercise price of $6.28 per share and expires October 1, 2033. It vests in 12 quarterly installments, beginning December 31, 2026, and ending September 30, 2029, subject to continued service with the issuer. Bowie reported direct ownership of 577,910 common shares on October 1, 2026.
EXOZYMES INC. (EXOZ) director Lon E. Bell received 10,000 stock options covering 10,000 shares of common stock, with an exercise price of $6.28 per share. Vesting is subject to his continued service, and the options expire October 1, 2033.
eXoZymes Inc. attached an investor presentation dated October 6, 2026, that may be provided to investment bankers, other offering participants, and current and potential investors in the company’s securities.
eXoZymes Inc. asks shareholders to elect six directors for one-year terms and ratify RBSM LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026. The board recommends a vote “FOR” both proposals. The virtual annual meeting is scheduled for November 13, 2026; shareholders of record on September 15, 2026 may vote.
As of September 15, 2026, 9,304,701 common shares were outstanding, and 4,652,351 shares are required for a quorum. The ownership table lists former parent and controlling shareholder MDB Capital Holdings, LLC as beneficially owning 4,136,426 shares, or 43.50%. President and CEO Michael Heltzen’s reported 2025 total compensation was $1,060,374. Chief Commercial Officer Damien Perriman’s employment terms provide for an equity award equal to 2.5% of the company’s total outstanding common shares, with 70% in stock options and the remainder in restricted stock units.
RBSM audit fees billed were $222,500 in 2025 and $145,000 in 2024. Proposal 1 is non-routine for broker voting, while proposal 2 is a routine matter brokers may vote on without shareholder instructions.